Scemblix® (asciminib)
Chronic Myeloid Leukemia (CML)
Key Facts
About Novartis
Novartis is a global pharmaceutical leader with a mission to reimagine medicine to improve and extend lives. With a market cap of $290.10B, it operates across 118 countries, reaching over 300 million patients annually. Its strategy focuses on delivering high-value medicines for society's greatest disease burdens through technology leadership in R&D and novel access approaches, powered by a diversified portfolio across oncology, cardiovascular, immunology, neuroscience, and rare diseases.
View full company profileTherapeutic Areas
Other Chronic Myeloid Leukemia (CML) Drugs
| Drug | Company | Phase |
|---|---|---|
| XS003 (nilotinib) | Xspray Pharma | NDA Submitted |
| TERN-701 | Terns Pharmaceuticals | Phase 3 |
| ELVN-001 | Enliven Therapeutics | Phase 1b |